Lupus Anticoagulant Comp

The Lupus Anticoagulant Comprehensive category includes specialized coagulation tests used to detect lupus anticoagulant activity, an immune-mediated clotting abnormality caused by antiphospholipid antibodies.

Lupus anticoagulants are antibodies that interfere with phospholipid-dependent clotting reactions in laboratory tests. Despite their name, they are associated with an increased risk of blood clots, not bleeding. Their presence is a defining feature of antiphospholipid syndrome (APS) and may also occur in individuals with systemic lupus erythematosus (SLE), other autoimmune diseases, infections, or transient immune activation.

This category evaluates how antiphospholipid antibodies affect clotting pathways using functional coagulation assays, including dilute Russell viper venom time (dRVVT), activated partial thromboplastin time (aPTT)-based assays, confirmatory ratios, and phospholipid neutralization tests. These tests help distinguish lupus anticoagulant activity from factor deficiencies, anticoagulant medications, or other causes of prolonged clotting times.

Lupus anticoagulant testing is commonly ordered in individuals with unexplained venous or arterial thrombosis, recurrent pregnancy loss, prolonged clotting results, or suspected autoimmune-related clotting disorders. Because results can be affected by medications or acute illness, a comprehensive, multi-step testing approach improves diagnostic accuracy.

Together, these biomarkers provide a structured assessment of immune-driven clotting risk, supporting diagnosis, risk stratification, and long-term management of antiphospholipid-related conditions.